Latest Research on Bipolar Disorder Treatment (2026): New Treatments, Studies & What Has Changed

The biggest change in bipolar disorder treatment in 2026 is not one miracle drug. It is better evidence for choosing between the treatments we already have, plus a few genuinely new options. Here is what changed this year and what it means if you or someone you love lives with bipolar disorder.

Key takeaways (updated November 2026)

• The largest evidence review ever was published in The BMJ in August 2026. It pooled 77 meta-analyses covering 116 treatments and launched a free, continuously updated treatment database.
• A new medicine was approved. The US FDA approved milsaperidone (Bysanti) on 20 February 2026 for acute manic or mixed episodes of bipolar I disorder.
• Lithium is still the cornerstone, but a 2026 study of over 165,000 patients shows which combinations work best when lithium alone is not enough.
• New mechanisms are in late-stage trials, including a muscarinic drug (xanomeline-trospium, KarXT) for mania.
• Ketamine augmentation now has meta-analytic support for bipolar depression, while psilocybin remains experimental and limited to small bipolar II studies.
• Personalised treatment is the direction of travel: genetics, lithium-response prediction and shared decision tools.

Medical note: This article summarises research for education. It is not a treatment plan. Never start, stop or change bipolar medication without your psychiatrist.

Latest bipolar disorder research at a glance (2025–2026)

These are the updates that matter most, newest first. Each one is explained in detail below.

What is the most effective treatment for bipolar disorder in 2026?

There is no single “best” treatment. The right choice depends on the phase of illness: mania, depression or long-term maintenance. The August 2026 BMJ review is the clearest answer so far, because it graded the certainty of evidence for every treatment in every phase.

The review covered 74 medicines, 18 brain stimulation methods, 13 nutraceuticals, 8 psychosocial therapies and 3 circadian treatments. Out of 2,510 treatment–outcome links, only 236 were backed by high-certainty evidence. (Source)

Three medicines showed benefit in all three phases: valproate, olanzapine and quetiapine. Lithium showed benefit in mania and maintenance. Lamotrigine and add-on CBT helped in depression and maintenance.

What the guidelines say. The CANMAT/ISBD guidelines, used worldwide, still list lithium as a first-line maintenance option. The 2023 evidence update summarised these recommendations across the lifespan. The BMJ review’s results have now been used to update the CANMAT/ISBD guidelines.

A higher position in a ranking does not make a medicine right for you. Weight gain, sedation, kidney or thyroid effects and past response all change the decision, which is why the researchers built a free preference tool at ebibd-database.org.

Lithium: what the latest research says

Lithium remains the reference treatment for long-term bipolar disorder. The new research is about using it better: who responds, how to keep it safe, and what to do when it is not enough.

1. When lithium alone is not enough (2026)

A Nature Mental Health study followed 165,540 people with bipolar disorder in Sweden and Finland for about nine years. Each person was compared with themselves across treatment periods, which reduces bias. Compared with lithium alone, the risk of psychiatric rehospitalisation was:

This is observational data, so it shows association, not proof. Clozapine also needs regular blood monitoring. But it gives psychiatrists real-world guidance when lithium fails or must be stopped.

2. Lithium and suicide prevention (2025)

An Acta Psychiatrica Scandinavica study of 296 outpatients compared 12 months without lithium with 12 months on lithium. It adds to evidence that lithium lowers both new episodes and suicidal behaviour.

3. Safety with monitoring (2025)

A 16-year Hong Kong study, published in JAMA Network Open, linked higher lithium blood levels with more thyroid problems and chronic kidney disease. The researchers concluded that lithium can be used safely with regular blood tests, and that it should stay a first-line option.

4. Predicting who will respond (2026)

Only about one in three people has an excellent response to lithium. The European R-LiNK study followed 169 people starting lithium for 24 months. Its early results link response to brain grey matter in the hippocampus and amygdala and to lithium’s distribution in the brain on special MRI. Separately, a polygenic score study found people in the top tenth of the score had about 3.5 times higher odds of responding well. Neither test is ready for routine clinics yet.

New treatments for bipolar disorder in 2026

One new medicine was approved in 2026, and several new approaches are in late-stage trials. None of the pipeline drugs below is available outside research studies yet.

Approved: milsaperidone (Bysanti)

The US FDA approved milsaperidone on 20 February 2026. It treats acute manic or mixed episodes of bipolar I disorder in adults, and schizophrenia.

• It is an atypical antipsychotic that blocks dopamine D2, serotonin 5-HT2A and alpha-adrenergic receptors.
• It is the active metabolite of iloperidone and converts into it in the body. Medscape notes iloperidone itself was approved for bipolar I disorder in 2024.
• Experts describe it as an incremental advance rather than a new mechanism. Side effects are expected to match iloperidone, including dizziness on standing and metabolic changes.
• US launch was planned for the third quarter of 2026. It is not yet available in India.

In phase 3 trials: xanomeline-trospium (KarXT) for mania

KarXT works on muscarinic acetylcholine receptors instead of blocking dopamine like every current antipsychotic. It is already approved for schizophrenia. Bristol Myers Squibb is now testing it in bipolar I mania in the BALSAM programme:

• BALSAM-2: KarXT alone for acute mania, inpatient, placebo-controlled.
• Adjunctive trial: KarXT added to lithium, valproate or lamotrigine; 424 participants; due to finish in 2027.

As of November 2026, we could not find published efficacy results for bipolar mania.

Earlier-stage trials for bipolar depression

• ABBV-932 (AbbVie): a phase 2 trial in about 160 adults with bipolar I or II depression, plus a 26-week open-label safety study.
• ABX-002: a small phase 2 open-label study as an add-on treatment for bipolar depression.
• Cariprazine in children: a trial is testing whether cariprazine, already approved for adult bipolar I depression, helps young people too. (Source)

Latest research on bipolar depression treatment

Bipolar depression lasts longer than mania for most people and has fewer proven treatments. This is where research is moving fastest.

Newer antipsychotics with strong evidence. Cariprazine, lumateperone and lurasidone all showed benefit across several outcomes in the 2026 BMJ review. They are often preferred because they treat depression without the high risk of switching into mania seen with antidepressants used alone.

Ketamine: now backed by meta-analysis. Ketamine augmentation was one of the treatments effective across several outcomes for adult bipolar depression in the BMJ review. An earlier systematic review found that 61% of people given intravenous ketamine on top of a mood stabiliser responded, compared with 5% on placebo. Effects appear within hours but can fade within one to two weeks. An overview of 26 reviews rated the overall certainty as low. Ketamine is for treatment-resistant cases under specialist supervision, always with a mood stabiliser.

Psilocybin: promising but experimental. People with bipolar disorder were excluded from psychedelic trials for decades because of mania risk. Recent small studies have started to test it carefully in bipolar II depression only:

• A 15-person open-label study in JAMA Psychiatry gave a single 25 mg dose with psychotherapy. Depression scores fell by an average of 24 points at three weeks.
• A 2026 pilot in the Journal of Clinical Psychiatry treated 14 people with a 10 mg dose first, then 25 mg if needed. There were no serious adverse events, and 4 people reached remission after the lower dose alone.

The authors themselves say randomised controlled trials are needed. Psilocybin has not been tested safely in bipolar I disorder, and it is illegal outside approved research in India.

What does not work well. Antidepressants on their own can trigger mania or rapid cycling in bipolar disorder. Fluoxetine appears in the evidence only in combination with olanzapine.

Brain stimulation: ECT, TMS and accelerated TMS

Brain stimulation is growing in bipolar depression, but the evidence is thinner than for medicines.

• ECT (electroconvulsive therapy) still has an established role in severe or treatment-resistant bipolar depression, severe mania, catatonia and situations needing rapid improvement. The 2026 BMJ review notes that these severely ill patients are hard to include in randomised trials, so missing high-certainty data does not mean ECT fails.
• rTMS and theta-burst stimulation were among 18 stimulation methods in the BMJ review. Many underlying reviews were rated low quality, so the benefit in bipolar depression is still uncertain.
• Accelerated TMS packs several sessions into each day, aiming for relief in days rather than weeks. A small randomised sham-controlled trial in JAMA Network Open (2025) tested it in 13 people with bipolar depression, after an earlier 24-patient trial. Stanford is running a larger sham-controlled trial in treatment-resistant bipolar II depression.

For now, TMS is an add-on option for selected patients, usually alongside a mood stabiliser to reduce the risk of switching into mania.

Current research studies: towards personalised treatment

The common thread in 2026 research is moving from trial and error to matching the right treatment to the right person.

• Living evidence platforms. The BMJ team’s EBI-BD database will be updated at least every two years. Its preference tool lets a patient and psychiatrist weigh 17 side effects, such as weight gain, sedation or kidney effects, and rank 12 common treatments accordingly.
• Lithium-response biomarkers. Brain imaging, blood signatures and genetic scores are being tested to predict lithium response before months of trial. The R-LiNK study also found its lithium-induced blood signature differed between men and women.
• Digital monitoring. An August 2026 systematic review in JMIR Mental Health found eight types of passive digital signals studied in bipolar disorder: physical activity, heart rate, skin conductance, location, phone use, light exposure, sleep and speech. Links to specific mood states are still inconclusive, so these tools are not yet ready to replace clinical review.
• Comorbidity-focused therapy. New trials target overlapping conditions, such as a group psychological programme for adults with both bipolar disorder and ADHD.

Psychotherapy, psychoeducation and lifestyle: what the research supports

Medicines work best when combined with structured support. The 2026 BMJ review gives these non-drug approaches real weight.

• Group psychoeducation helps prevent relapse when added to medication. People learn to spot early warning signs, keep regular routines and stay on treatment.
• Cognitive behavioural therapy (CBT) as an add-on showed benefit in both bipolar depression and maintenance.
• Circadian and sleep-based treatments were assessed as a separate group, reflecting how closely sleep disruption is tied to mood episodes.
• Diet research is at an early stage. One US trial is testing a 16-week ketogenic diet in young people aged 12–21 with bipolar depression. Do not try this without medical supervision, especially on lithium.

Adherence is the hidden problem. Nearly half of people with bipolar disorder may not take treatment as prescribed, often because of side effects or not being involved in decisions. Shared decision-making is one of the clearest themes of 2026 research.

What this research means for patients in India

Most of the medicines with the strongest evidence, including lithium, valproate, quetiapine, olanzapine, lamotrigine, aripiprazole and lurasidone, are already widely available in India. Newer options such as milsaperidone, KarXT and psilocybin are not. The practical takeaway is to use proven treatments well, rather than waiting for a new drug.

Questions to ask your psychiatrist:

1. Which phase am I in now, and is my treatment chosen for that phase?
2. Am I a good candidate for lithium, and how often should my kidney and thyroid be checked?
3. If my current medicine is not working, what are the evidence-based next steps?
4. Which side effects matter most to me, and how do the options compare?
5. Would psychoeducation or CBT help me stay well?

If you are unsure about symptoms, read our guide to bipolar disorder symptoms, mania and hypomania. Not sure who to see first? Our article on psychiatrist vs psychologist explains the difference.

Anvaya Healthcare offers online bipolar disorder treatment with psychiatrists and psychologists anywhere in India. If you prefer in-person care, you can consult the best psychiatrist in Delhi for bipolar disorder at our clinics.

If you are in crisis: If you or someone you know is thinking about suicide, contact Tele-MANAS on 14416 or go to the nearest emergency department.

Frequently asked questions

What is the latest treatment for bipolar disorder?

The newest approved medicine is milsaperidone (Bysanti), approved by the US FDA in February 2026 for acute mania in bipolar I disorder. KarXT, a drug with a new muscarinic mechanism, is in phase 3 trials for mania.

What is the most effective treatment for bipolar disorder?

It depends on the phase. Lithium remains a first-line choice for long-term prevention. Valproate, olanzapine and quetiapine have evidence across mania, depression and maintenance. Cariprazine, lumateperone and lurasidone have strong evidence for bipolar depression.

What is the first-line treatment for bipolar disorder?

International guidelines such as CANMAT/ISBD list lithium as a first-line maintenance treatment, along with several antipsychotics and mood stabilisers depending on the phase.

Is lithium still used for bipolar disorder in 2026?

Yes. 2025–2026 studies confirm it prevents relapse and suicidal behaviour, and is safe with regular blood tests for lithium level, kidney and thyroid function.

Is there a cure for bipolar disorder?

No. Bipolar disorder is a long-term condition, but most people can stay well for long periods with the right treatment and support.

Can ketamine or psilocybin treat bipolar depression?

Ketamine has meta-analytic support as an add-on for treatment-resistant bipolar depression under specialist care. Psilocybin is experimental and has only been tested in small bipolar II studies.

What are the NICE guidelines for bipolar disorder?

NICE guideline CG185 covers the assessment and management of bipolar disorder in the UK. It recommends offering lithium as the first-line long-term medicine. Its December 2023 update says valproate should not be started in anyone under 55 unless two specialists agree there is no suitable alternative, because of reproductive risks.

References

1. De Prisco M, et al. Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review (U-REACH). BMJ 2026;394:e100216. doi:10.1136/bmj-2026-100216
2. de Quevedo JL. Treating bipolar disorder across the lifespan: what does the best available evidence tell us? UTHealth Houston, September 2026.
3. Lieslehto J, et al. Comparative effectiveness of treatment strategies for bipolar disorder during and after lithium treatment. Nature Mental Health 2026.
4. FDA approval of Bysanti (milsaperidone). UTHealth Houston, February 2026; Medscape.
5. Chan JKN, et al. Lithium for bipolar disorder and risk of thyroid dysfunction and chronic kidney disease. JAMA Network Open 2025.
6. Pompili M, et al. New episodes and suicidal risks during versus before long-term treatment with lithium. Acta Psychiatrica Scandinavica 2025;152(4):290–298.
7. Bellivier F. Predictive biomarkers of lithium response: preliminary results from the European R-LiNK initiative. European Psychiatry 2026.
8. Polygenic score and lithium treatment response in bipolar disorder. University of Cagliari.
9. ClinicalTrials.gov: NCT06951711, NCT07140913, NCT06605599, NCT07220460, NCT06869187, NCT05849402, NCT07039903.
10. Bahji A, Zarate CA, Vazquez GH. Ketamine for bipolar depression: a systematic review. Int J Neuropsychopharmacol 2022.
11. Rodolico A, et al. Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression. Frontiers in Psychiatry 2024.
12. An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar II depression. J Clin Psychiatry 2026;87(4).
13. Aaronson ST, et al. Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar II depression. JAMA Psychiatry 2024.
14. Appelbaum LG, et al. Accelerated TMS in bipolar depression: a randomized sham-controlled trial. JAMA Network Open 2025.
15. Kutcher TP, et al. Digital markers for passive remote monitoring of bipolar disorder: systematic review. JMIR Mental Health 2026.
16. Keramatian K, Chithra NK, Yatham LN. The CANMAT and ISBD guidelines for the treatment of bipolar disorder: summary and a 2023 update of evidence. Focus 2023.
17. NICE. Bipolar disorder: assessment and management (CG185).

Last reviewed: November 2026. This article will be updated as new research is published.